Improved blood preservation with 0.5CPD Erythro-Sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood

Vox Sanguinis

Volumn 74, Issue 3, 1998, Pages 168-175

  Solheim, Bjarte G ^a   Bergerud, U E ^a   Kjeldsen Kragh, J ^a   Brosstad, F ^a   Mollnes, T E ^b,c   Hogman C F ^d   Eriksson, L ^d   Schutz, R ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORDLAND HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; BLOOD CLOTTING FACTOR 8; PROTHROMBIN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD COMPONENT; BLOOD STORAGE; COMPLEMENT ACTIVATION; ERYTHROCYTE; ERYTHROCYTE METABOLISM; ERYTHROCYTE PRESERVATION; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

2,3-DIPHOSPHOGLYCERATE; BLOOD PRESERVATION; CELL SEPARATION; CITRIC ACID; COLD; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FACTOR VIII; HEMOLYSIS; ISOTONIC SOLUTIONS; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PROTHROMBIN; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 0031982139     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030926     Document Type: Article

References (19)

1. Prowse C, Waterston YG, Dawes J, Farmgia A: Studies on the procurement of blood coagulation factor VIII: In vitro studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1987;52:257-264.
2. Griffin B, Bell K, Prowse C: Studies on the procurement of blood coagulation factor VIII: In vivo studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1988;54:193-198.
3. Griffin B, Bell K, Prowse C: Studies on the procurement of blood coagulation factor VIII: In vitro studies on blood components prepared in half-strength citrate anticoagulant 18 hours after phlebotomy. Vox Sang 1988;55:9-13.
4. Farrugia A, Douglas S, James J, Whyte G, Herrington R: Use of plasma with high levels of ionised calcium in the production of model scale coagulation factor concentrates. Thromb Haemostasis 1990;64:374-378.
5. McIntosh RV, Foster PR: The effect of solution formulation on the stability and surface interactions of factor VIII during plasma fractionation. Transfus Sci 1990;11:55-66.
6. Suontaka AM, Åkerblom O, Blombäck M, ErikssonL, Högman CF, Payrat JM: Stability of blood coagulation factors and inhibitors in blood drawn into half strength citrate coagulant. Vox Sang 1996;71:97-102.
7. Farrugia A, Douglas S, James J, Whyte G: Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: Improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells. Vox Sang 1992;63:31-38.
8. Pieterz RNI, de Korte D, Reesink HW, Dekker WIA, van den Ende A, Loos JA: Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989;56:145-150.
9. Högman CF, Eriksson L, Gong J, Högman AB, Vikholm K, Debrauwere J, Payrat JM, Stewart M: Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use. Vox Sang 1993;65:271-278.
10. Högman CF, Eriksson L, Gong J, Vikholm K, Debrauwere J, Payrat JM. Half-strength citrate CPD and new additive solutions for improved blood preservation. 2. The effect of storage at ambient temperature before component preparation and different means of supplying glucose to the red cells. Transfus Med 1993;3:211-222.
11. Duguid J, Winkelman L, Feldman P, Brady A-M: The effect of citrate anticoagulants on apheresed plasma. Transfus Sci 1989;10:287-293.
12. Recommendation No. R (95) 15 on the preparation, use and quality assurance of blood components. Strasbourg, Council of Europe, 1995.
13. Högman CF, Eriksson L, Ericson A, Reppucci AJ: Storage of saline-adenine-glucose-mannitol-suspended red cells in a new plastic container: Polyvinyl chloride plasticized with butyryl-n-trihexyl-citrate. Transfusion 1991;31:26-29.
14. Garred P, Mollnes TE, Lea T: Quantification in enzyme-linked immunosorbent of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988;27:329-335.
15. Mollnes TE, Lea T, Fröland SS, Harboe M: Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985;22:197-202.
16. Hunter FT. Grove-Rasmussen M, Soutter L: A spectrophotometric method for quantitating hemoglobin in plasma or serum. Am J Clin Pathol 1950;20:429-433.
17. Fleisch H: Mesure de l'hémolyse par détermination dans le plasma de l'hémoglobine, la méthémalbumine et leurs dérivés. Helv Med Acta 1960;27:383-407.
18. Mollnes TE, Garred P, Bergseth G: Effect of time, temperature and anticoagulants on in vitro complement activation: Consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988;73:484-488.
19. de Verdier CH, Ericson Å: 3,6 D-glycerate 2,3-bisphosphate; in Bergmeyer HU, Bergmeyer J, Grassl M (eds): Methods of Enzymatic Analysis, ed 3. Metabolites 1. Carbohydrates. Weinheim, Verlag Chemie. 1984. vol 6, pp 547-555.